DSGN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 May 2024 @ 16:00):

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions...

Stats
Today's Volume	108 276
Average Volume	312 165
Market Cap	254.23M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-0.250 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.33
ATR14	$0.00500 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Schmid John P.	Buy	17 809	Common Stock
2024-03-22	Schmid John P.	Buy	9 156	Common Stock
2024-03-25	Berger Heather A.	Buy	1 300	Common Stock
2024-03-13	Kim Jae B.	Sell	0	Common Stock
2024-03-13	Kim Jae B.	Sell	315 000	Stock Option (right to buy)

INSIDER POWER
76.05
Last 96 transactions
Buy: 40 774 561 \| Sell: 39 424 073

Volume Correlation

Long: -0.05 (neutral)

Short: 0.16 (neutral)

Signal:(54.701) Neutral

Design Therapeutics, Inc. Correlation

10 Most Positive Correlations
DRNA	0.955
ICPT	0.95
TWLVU	0.945
GRNV	0.943
MTSL	0.933
ENOB	0.931
VITL	0.929
INCR	0.928
TFFP	0.927
SIGA	0.926

10 Most Negative Correlations
AGFS	-0.948
SBNYP	-0.94
NECB	-0.94
ATAK	-0.939
PTMN	-0.934
LWAC	-0.929
HOFT	-0.928
IVAC	-0.927
RMGC	-0.924
LRFC	-0.92

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Design Therapeutics, Inc. Correlation - Currency/Commodity

0.57
( weak )

0.39
( neutral )

0.00
( neutral )

0.53
( weak )

-0.81
( strong negative )

-0.36
( neutral )

Design Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-537 000 (0.00 %)
EPS:	$-1.190

FY	2023
Revenue:	$0
Gross Profit:	$-537 000 (0.00 %)
EPS:	$-1.190

FY	2022
Revenue:	$0
Gross Profit:	$-466 000 (0.00 %)
EPS:	$-1.050

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.644

Financial Reports:

No articles found.

Design Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.